Friday, May 30, 2025

Latest

Revive Therapeutics Granted FDA Approval For Phase 3 Clinical Trial For Bucillamine In COVID-19 Treatment

It’s a big day for Revive Therapeutics (CSE: RVV) (OTC: RVVTF). The company announced this morning that the US Food and Drug Administration has approved the company’s application for a Phase 3 Clinical Trial for the study of utilizing Bucillamine in the treatment of patients with mild-moderate COVID-19.

The Phase 3 clinical trial will see a randomized, double-blind, placebo-controlled confirmatory study conducted to evaluate the safety and efficacy of Bucillamine in the treatment of the infectious disease. The clinical study, entitled, “A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of Bucillamine in Patients with Mild-Moderate COVID-19,” will see up to 1,000 patients enrolled for testing.

Under the study, patients will be randomized 1:1:1 initially to test the efficacy of two different dosages of Bucillamine in the treatment of COVID-19, with one group being subject to a placebo. Dosages will be administered for a period of up to 14 days, with the objective being to compare frequency of hospitalization or death in patients with mild-moderate COVID-19 among the three groups.

Efficacy of Bucillamine under the study will be analyzed based on a number of factors, including clinical outcome, disease severity, supplemental oxygen use, and progression of the disease among those whom receive the drug and those of whom receive a placebo.

After 210 patients have been studied for a period of 28 days, the study will then select the better performing dosage of Bucillamine and study it on on 2:1 basis with that of a placebo to further study the efficacy of the drug.

The company intends to execute on the Phase 3 clinical trial in an “expeditious manner.” Full scientific rationale for the use of Bucillamine in the treatment of infectious diseases such as COVID-19 can be found here

Revive Therapeutics last traded at $0.24 on the CSE.


FULL DISCLOSURE: Revive Therapeutics is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Revive Therapeutics on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Leave a Reply

Video Articles

How To Profit From $3300 Gold? An Inside Look At A Massive 300,000 Oz Project | Martino De Ciccio

We’re At The Start of a Great Silver Boom | Ross McElroy & Andy Bowering – Apollo Silver Corp

Equinox Gold Q1 Earnings: When Everything Goes Wrong

Recommended

Sterling Metals Hits 0.21% Copper Over 482.8 Metres In First Drilling At Soo Copper project

First Majestic Makes Second Major Discovery At Santa Elena In Just A Year

Related News

Consumer Confidence Falls to Lowest Level since March 2017; Dropping 9.5%

This morning the The Conference Board announced the Consumer Confidence Index declined sharply dropping 9.5%...

Tuesday, March 31, 2020, 01:03:19 PM

Revive Therapeutics And The Psychedelic Revolution

A massive psychedelics boom is already here. In fact, with the potential to treat a wide...

Sunday, June 21, 2020, 10:30:00 AM

US Consumer Sentiment Slumps to Decade Low Amid Delta Variant, Inflation Concerns

Americans’ optimism surrounding the recovery of the US economy slumped to the lowest in a...

Sunday, August 15, 2021, 03:05:00 PM

Meat Processing Plants Turning to Robot Butchers to Reduce Coronavirus Infection Rates Among Workers

As the coronavirus pandemic continues to sweep across the US with record breaking infection rates,...

Sunday, July 12, 2020, 03:01:00 PM

Canadian Wholesale Trade Fell by 21.6% in April Amid Coronavirus Pandemic

The coronavirus pandemic caused many businesses across Canada to shut their doors, while consumers were...

Friday, June 19, 2020, 12:41:00 PM